Drug - Incruse® Ellipta® (umeclidinium) [GlaxoSmithKline]
Therapeutic area - COPD
Patients must meet all of the following criteria:
- Patient has a diagnosis of COPD AND
- Patient is age 18 or older AND
- Patient has tried and failed Spiriva OR has a contraindication to Spiriva as documented in clinical progress notes
Patient’s most current body weight must be provided at time of request.
Incruse Ellipta is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
MHCP Provider Call Center 651-431-2700 or 800-366-5411